The estimated Net Worth of Faith L. Charles is at least $53.4 millier dollars as of 26 April 2024. Faith Charles owns over 7,550 units of Cns Pharmaceuticals Inc stock worth over $12,532 and over the last 3 years Faith sold CNSP stock worth over $40,900.
Sign up
Faith Charles CNSP stock SEC Form 4 insiders trading
Faith has made over 2 trades of the Cns Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Faith bought 7,550 units of CNSP stock worth $24,764 on 26 April 2024.
The largest trade Faith's ever made was selling 8,330 units of Cns Pharmaceuticals Inc stock on 27 September 2023 worth over $40,900. On average, Faith trades about 1,444 units every 19 days since 2021. As of 26 April 2024 Faith still owns at least 78,323 units of Cns Pharmaceuticals Inc stock.
You can see the complete history of Faith Charles stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Faith Charles's mailing address?
Faith's mailing address filed with the SEC is 6555 CARNEGIE AVE, 4TH FLOOR, , CLEVELAND, OH, 44103.
Insiders trading at Cns Pharmaceuticals Inc
Over the last 5 years, insiders at Cns Pharmaceuticals Inc have traded over $132,960 worth of Cns Pharmaceuticals Inc stock and bought 509,021 units worth $458,622 . The most active insiders traders include Christopher Downs, John M Climaco et Waldemar Priebe. On average, Cns Pharmaceuticals Inc executives and independent directors trade stock every 79 days with the average trade being worth of $6,051. The most recent stock trade was executed by Jerzy Gumulka on 1 February 2024, trading 33,333 units of CNSP stock currently worth $10,000.
What does Cns Pharmaceuticals Inc do?
cns pharmaceuticals, inc., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. the company's lead drug candidate is berubicin, which completed phase i clinical trial that is used for the treatment of glioblastoma multiforme. it has license agreements with houston pharmaceuticals, inc. and the university of texas m.d. anderson cancer center; and a development agreement with wpd pharmaceuticals inc. cns pharmaceuticals, inc. was founded in 2017 and is based in houston, texas.
What does Cns Pharmaceuticals Inc's logo look like?
Complete history of Faith Charles stock trades at Abeona Therapeutics Inc, Avenue Therapeutics Inc et Cns Pharmaceuticals Inc
Cns Pharmaceuticals Inc executives and stock owners
Cns Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
John Michael Climaco Esq., J.D.,
Chairman, CEO & Pres -
Christopher S. Downs CPA, CTP, FP&A,
Chief Financial Officer -
Dr. Sandra L. Silberman M.D., Ph.D.,
Chief Medical Officer -
Dr. Donald H. Picker Ph.D.,
Chief Science Officer -
Dr. Waldemar Priebe Ph.D.,
Founder & Chairman of the Scientific Advisory Board -
Amy Mahery,
Director -
Biosciences, Inc. Cortice,
-
Christopher Downs,
Chief Financial Officer -
Jerzy Gumulka,
Director -
Carl Anthony Evans,
Director -
Jeffry R. Keyes,
Director -
John M Climaco,
Chief Executive Officer -
Waldemar Priebe,
-
Faith L. Charles,
Director -
Bettina M. Cockroft,
Director